Bicara Therapeutics BCAX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's total equity?
- Bicara Therapeutics (BCAX) reported total equity of $513.96M in Q1 2026.
- How has Bicara Therapeutics's total equity changed year-over-year?
- Bicara Therapeutics's total equity increased by 12.0% year-over-year, from $458.96M to $513.96M.
- What is the long-term trend for Bicara Therapeutics's total equity?
- Over 3 years (2022 to 2025), Bicara Therapeutics's total equity has grown at a 59.6% compound annual growth rate (CAGR), from -$98.8M to $401.45M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.